Floatz logo

Mayzent

Secondary Progressive Multiple Sclerosis (SPMS)

State University of New York at BuffaloPhase 2/3Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

36 Active assets in the Secondary Progressive Multiple Sclerosis (SPMS) cohort.

Asset / SponsorPhaseRating
Siponimod
Novartis Pharmaceuticals
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Cairo University
Phase 3BB
bnt162
Novartis Pharmaceuticals
Phase 4BB
mis416
Innate Immunotherapeutics
Phase 2BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →